Damora Therapeutics Inc (DMRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 14,175 | 19,678 | 22,862 | 21,091 | 21,465 |
| Marketable Securities | N/A | N/A | N/A | 6,080 | 11,686 |
| TOTAL | $16,839 | $21,178 | $25,168 | $30,541 | $36,774 |
| Non-Current Assets | |||||
| PPE Net | N/A | 62 | 67 | 73 | 78 |
| Other Non-Current Assets | 236 | 2,136 | 2,062 | 1,863 | 1,375 |
| TOTAL | $236 | $2,198 | $2,129 | $1,936 | $1,453 |
| Total Assets | $17,132 | $23,376 | $27,297 | $32,477 | $38,227 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 377 | 503 | 724 | 1,665 | 1,702 |
| Accrued Expenses | 820 | 1,938 | 2,985 | 2,653 | 4,128 |
| TOTAL | $1,197 | $2,441 | $3,709 | $4,318 | $5,830 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 104 | 0 | 0 | 0 | 66 |
| TOTAL | $104 | $N/A | $N/A | $N/A | $66 |
| Total Liabilities | $1,301 | $2,441 | $3,709 | $4,318 | $5,896 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,322 | 1,317 | 1,085 | 1,085 | 1,085 |
| Retained earnings | -277,524 | -270,783 | -266,900 | -261,562 | -256,085 |
| Other shareholders' equity | 97 | 665 | 197 | 326 | 380 |
| TOTAL | $15,831 | $20,935 | $23,588 | $28,159 | $32,331 |
| Total Liabilities And Equity | $17,132 | $23,376 | $27,297 | $32,477 | $38,227 |